Kurs
+0,95%
Kurs
+0,95%
Open
159,50
High
162,50
Low
159,50
Close
160,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
2,09 MNOK
Likviditet
2,09 MNOK
Rel. mcap
0,07%
Antal aktier
12 989
Likviditet under dagen för detta pressmeddelande
Kalender
Tid* | ||
2025-10-24 | 09:00 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 09:00 | Kvartalsrapport 2025-Q2 |
2025-05-09 | 09:00 | Kvartalsrapport 2025-Q1 |
2025-05-08 | N/A | Årsstämma |
2025-02-28 | 14:30 | Bokslutskommuniké 2024 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-08-16 | - | Kvartalsrapport 2024-Q2 |
2024-04-25 | - | Kvartalsrapport 2024-Q1 |
2024-04-25 | - | X-dag ordinarie utdelning MEDI 4.50 NOK |
2024-04-24 | - | Årsstämma |
2024-02-29 | - | Bokslutskommuniké 2023 |
2023-10-27 | - | Kvartalsrapport 2023-Q3 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-04-25 | - | Kvartalsrapport 2023-Q1 |
2023-04-25 | - | X-dag ordinarie utdelning MEDI 4.50 NOK |
2023-04-24 | - | Årsstämma |
2023-03-01 | - | Bokslutskommuniké 2022 |
2022-10-28 | - | Kvartalsrapport 2022-Q3 |
2022-08-23 | - | Kvartalsrapport 2022-Q2 |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-04-28 | - | X-dag ordinarie utdelning MEDI 3.75 NOK |
2022-04-27 | - | Årsstämma |
2022-02-25 | - | Bokslutskommuniké 2021 |
2021-10-22 | - | Kvartalsrapport 2021-Q3 |
2021-08-13 | - | Kvartalsrapport 2021-Q2 |
2021-04-28 | - | X-dag ordinarie utdelning MEDI 3.00 NOK |
2021-04-27 | - | Årsstämma |
2021-04-27 | - | Kvartalsrapport 2021-Q1 |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-10-22 | - | Kvartalsrapport 2020-Q3 |
2020-10-22 | - | X-dag ordinarie utdelning MEDI 2.75 NOK |
2020-08-14 | - | Kvartalsrapport 2020-Q2 |
2020-04-29 | - | Kvartalsrapport 2020-Q1 |
2020-04-28 | - | Årsstämma |
2020-04-03 | - | Extra Bolagsstämma 2020 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-08-20 | - | Kvartalsrapport 2019-Q2 |
2019-04-25 | - | Kvartalsrapport 2019-Q1 |
2019-04-25 | - | X-dag ordinarie utdelning MEDI 2.25 NOK |
2019-04-24 | - | Årsstämma |
2019-03-15 | - | Bokslutskommuniké 2018 |
2019-02-27 | - | Bokslutskommuniké 2018 |
2018-10-25 | - | Kvartalsrapport 2018-Q3 |
2018-08-15 | - | Kvartalsrapport 2018-Q2 |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-04-26 | - | X-dag ordinarie utdelning MEDI 2.00 NOK |
2018-04-25 | - | Årsstämma |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-10-24 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-04-27 | - | Kvartalsrapport 2017-Q1 |
2017-04-27 | - | X-dag ordinarie utdelning MEDI 1.75 NOK |
2017-04-26 | - | Årsstämma |
2017-02-17 | - | Bokslutskommuniké 2016 |
2016-10-19 | - | Kvartalsrapport 2016-Q3 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-04-20 | - | X-dag ordinarie utdelning MEDI 1.65 NOK |
2016-04-19 | - | Årsstämma |
2016-03-01 | - | Bokslutskommuniké 2015 |
2015-10-23 | - | Kvartalsrapport 2015-Q3 |
2015-08-19 | - | Kvartalsrapport 2015-Q2 |
2015-04-24 | - | Kvartalsrapport 2015-Q1 |
2015-04-24 | - | X-dag ordinarie utdelning MEDI 1.40 NOK |
2015-04-23 | - | Årsstämma |
2015-02-26 | - | Bokslutskommuniké 2014 |
2014-10-23 | - | Kvartalsrapport 2014-Q3 |
2014-08-20 | - | Kvartalsrapport 2014-Q2 |
2014-04-25 | - | Kvartalsrapport 2014-Q1 |
2014-04-24 | - | X-dag ordinarie utdelning |
2014-04-23 | - | Årsstämma |
2014-02-20 | - | Bokslutskommuniké 2013 |
2013-10-24 | - | Kvartalsrapport 2013-Q3 |
2013-08-20 | - | Kvartalsrapport 2013-Q2 |
2013-04-26 | - | X-dag ordinarie utdelning |
2013-04-25 | - | Årsstämma |
2013-04-25 | - | Kvartalsrapport 2013-Q1 |
2013-03-08 | - | Kapitalmarknadsdag 2013 |
2013-02-28 | - | Bokslutskommuniké 2012 |
2012-10-25 | - | Kvartalsrapport 2012-Q3 |
2012-08-24 | - | Kvartalsrapport 2012-Q2 |
2012-04-27 | - | Kvartalsrapport 2012-Q1 |
2012-04-27 | - | X-dag ordinarie utdelning |
2012-04-26 | - | Årsstämma |
2012-02-22 | - | Bokslutskommuniké 2011 |
2011-10-28 | - | Kvartalsrapport 2011-Q3 |
2011-08-24 | - | Kvartalsrapport 2011-Q2 |
2011-04-29 | - | Kvartalsrapport 2011-Q1 |
2011-04-29 | - | X-dag ordinarie utdelning |
2011-04-28 | - | Årsstämma |
2011-02-18 | - | Bokslutskommuniké 2010 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Medicinteknik |
2025-01-31 10:03:20
(Oslo, 31 January 2025) Medistim ASA (OSE: MEDI) is a niche market leader within
ultrasound technology with headquarters in Oslo, Norway. Medistim develops and
commercializes medical equipment for use within cardiac, vascular and transplant
surgery.
Today, the company announces the strengthening of its commercial operations with
the appointment of Mr. Mike Karim as Chief Commercial Officer (CCO), reporting
to the President and CEO. Mr. Karim brings deep industry expertise, strategic
insight, and a proven track record from leadership roles at esteemed companies
such as Boston Scientific, Lombard Medical, HeartWare, and Oxford Endovascular,
with a focus on the cardiac and vascular fields. With a strong foundation in
sales, he has led Sales, Marketing, and General Management functions,
successfully driving growth in international markets.
Furthermore, leadership of Medistim's AMERICAS sales region-including its
largest current market and greatest growth opportunity, the USA-has been
entrusted to Mr. Tony Winter. Mr. Winter brings extensive commercial leadership
experience across the cardiac, vascular, interventional, and surgical sectors.
With more than a decade at Medtronic, contributions to Synovis Life
Technologies, and most recently, leadership of the U.S. sales organization at
ACIST Medical Systems, he is well-positioned to drive Medistim's continued
expansion in the region.
"Medistim stands at a pivotal moment as we enter 2025, poised for significant
growth driven by the launch of the INTUI software platform, which is advancing
innovation in the Cardiac segment, and a focused strategy in the Vascular
segment, supported by the PATENT study and our commitment to advancing
Peripheral Bypass," says Medistim President and CEO Kari E. Krogstad. "This is
the perfect time to strengthen our commercial efforts. With these strategic
additions to our team, enhanced commercial initiatives, and a focus on fostering
collaboration and sharing best practices across all regions, I am confident we
will accelerate growth throughout this year and beyond."
In his CCO role, Mr. Karim will lead and support the efforts of Tony Winter
(AMERICAS), Stephanie Stenhagen (EMEA), and Roger Morberg (APAC) as they
continue driving Medistim's growth and success.
About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, UK,
Spain, Denmark, Sweden and Norway, in addition to more than 60 distributors in
Europe, Asia, Middle East, Africa, and South America. For more information,
visit the Medistim home page: www.medistim.com
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com